Global life sciences leader Thermo Fisher Scientific has introduced a new integrated platform designed to accelerate and scale cell therapy manufacturing, marking a significant advancement in the rapidly evolving field of advanced therapeutics. The platform brings together end to end solutions across the cell therapy workflow
Global life sciences leader Thermo Fisher Scientific has announced an agreement to sell its microbiology business to European private equity firm Astorg for approximately $1.075 billion. The move is part of Thermo Fisher’s ongoing strategy to streamline its portfolio and focus on high growth, high
Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully
Indegene, a digital-first life sciences commercialization company, today announced the launch of a new center in London. This aligns with the company’s long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready. Indegene’s Europe-based clients can now
Everest Group, a leading global research and consulting firm, has recognized Indegene as a front-runner in generative AI (GenAI) life sciences market adoption. In its report, 'AI-deas to Action: Operationalizing Generative AI in Life Sciences', Everest Group acknowledged Indegene’s comprehensive GenAI capabilities, including scale, breadth
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crores Syngene International Limited today announced its third quarter financial results. Reported revenue from operations was up by 11% year-on-year to Rs. 944
Indegene, a digital-first life sciences commercialization company, announced a new center in Hyderabad to strengthen its global delivery operations and better address growing business needs. As the pharma industry faces increasing pressure to innovate and adapt, this new center will play a key role in helping companies accelerate their
Revenue from operations increased sequentially by 13% to Rs. 891 crores, down 2% year-on-year First half FY25 revenue was broadly flat, in line with our guidance, at Rs. 1,681 crores Syngene International Limited today announced its second quarter and half year financial results. Revenue from
Indegene today announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, thereby driving faster innovation at scale. Indegene and Microsoft have committed to developing resources in highly specialized and skilled medical
Full-year revenue from operations up 9% to Rs 3,489 Cr, PAT1 up 12% to Rs 519 Cr Fourth quarter revenue from operations declined 8% year-on-year to Rs. 917 Cr, PAT1 increased 6% to Rs. 189 Cr Syngene International Limited today announced its full-year
